ライフサイエンスコーパス: blind trial

1 tions) was a prospective, randomized, double-blind trial.

2 nce were entered into this crossover, double-blind trial.

3 re and reduced ejection fraction in a double-blind trial.

4 in a randomized, placebo-controlled, double-blind trial.

5 r placebo (n = 31) for 7 days in this double-blind trial.

6 has not been studied in a controlled, double-blind trial.

7 (TEAR) study is a 2-year, randomized, double-blind trial.

8 in a randomized, placebo-controlled, double-blind trial.

9 ntre, randomised, placebo-controlled, double-blind trial.

10 o GA or placebo (PBO) in this 3-year, double-blind trial.

11 ed, multi-center, placebo-controlled, double-blind trial.

12 GNITE4 was a prospective, randomized, double-blind trial.

13 wal, multicenter, placebo-controlled, double-blind trial.

14 llel-group, randomised, controlled, observer-blind trial.

15 Pilot single-blind trial.

16 ings from open-label series and small double-blind trials.

17 CDI recurrence in 2 large randomized, double-blind trials.

18 orrectly classified 9 of 10 chemicals in the blinded trial.

19 oses of IA (n = 52) in an open-label, single-blinded trial.

20 s with up to 90% accuracy in an independent, blinded trial.

21 ction in a single center, randomized, double-blinded trial.

22 doses of IA (N=52) in an open-label, single-blinded trial.

23 ia toxoid vaccine in a multicenter, observer-blinded trial.

24 prospective, randomized, multicenter, single-blinded trial.

25 any different AEs have been reported than in blinded trials.

26 In a single-blind trial, 106 individuals with TMJ closed lock were r

27 intravenously in a placebo-controlled double-blind trial, 2 weeks after which patients were challenge

28 In a randomized controlled blinded trial, 2-year-old purpose-bred beagles (n = 24),

29 control.In a randomized, controlled, double-blinded trial, 220 participants aged 18-60 y with body m

30 In this randomized, 2 x 2 factorial, double-blind trial, 2400 infants were randomly assigned to rece

31 this randomized, placebo-controlled, double-blind trial, 25 patients were treated with either sorivu

32 multicenter, randomized, controlled, double-blind trial, 340 HIV-1-positive adults not on antiretrov

33 n this randomized, active-controlled, double-blinded trial, 444 adults 60 through 64 years of age wer

34 Data were pooled from 10 double-blind trials (6699 patient-years of follow-up).

35 In a prospective, double-blind trial, acute liver failure patients without clinic

36 In this multicenter, randomized, double-blind trial, adolescent and adult patients (age, >/=12 y

37 In a randomized, double-blind trial, adults with acute bacterial skin and skin s

38 e assay was also successfully evaluated in a blind trial against analysing 60 samples from different

39 In a 12-week randomized, double-blind trial, ALS and MS patients with clinically signifi

40 (N=50) or placebo (N=53) in a 9-week double-blind trial and 4-week follow-up assessment.

41 Salaam, Tanzania, were enrolled in a double-blind trial and provided daily supplements of preformed

42 ow-income settings: concerns associated with blinded trials and the need for objective outcomes.

43 This randomized double-blind trial assessed the potential additional impact of

44 first placebo controlled, randomized double blinded trial assessing the efficacy and tolerability of

45 We performed a single-blind trial at 11 hospitals in Spain from May 2016 throu

46 did a randomised, placebo-controlled, double-blind trial at 29 UK secondary and tertiary hospitals of

47 We performed a double-blind trial at a tertiary care hospital in India.

48 We did this multicentre, double-blind trial at four general hospitals in northern Italy.

49 rallel-treatment, placebo-controlled, double-blind, trial at 81 sites in the Europe and the USA, adul

50 nducted a prospective, randomized, evaluator-blinded trial at three medical centers.

51 t pairs were enrolled in a randomised double-blind trial between September, 2001, and October, 2004,

52 In this multicentre, double-blind trial, between Oct 21, 2013, and Oct 30, 2014, we

53 G) conducted a randomized, phase III, double-blind trial, BIG 1-98, which enrolled 8,010 postmenopaus

54 Two phase 3 multicenter, randomized, double-blind trials carried out from 2007 to 2010.

55 In this multicenter, randomized, single-blinded trial, CF-RF and 2 different regimens of cryobal

56 In this parallel placebo-controlled double-blinded trial, children aged 3-12 years with >4 weeks of

57 This multicenter, randomized, double-blind trial compared fluconazole (N = 295) versus vorico

58 Randomized, controlled, double-blind trial compared RRR-alpha-tocopherol (1200 IU/d for

59 This randomized double-blind trial compared the impact of PCV13 versus PCV7 on

60 eview Board (IRB)-approved randomised double-blind trial comparing active to sham deep brain stimulat

61 A 24-week randomized double-blind trial comparing ALC (3,000 mg per day) with placeb

62 nfarction Study 48) was a randomized, double-blind trial comparing edoxaban with warfarin in patients

63 We performed a post hoc analysis of a double-blind trial comparing fondaparinux with placebo.

64 prospective, randomized, multicenter, double-blind trial comparing polymer-free SES with placebo-coat

65 We conducted a randomized, double-blind trial comparing salmeterol at a dose of 50 microg

66 ANTS: Randomized, placebo-controlled, double-blind trial conducted at 2 US academic hospitals among 5

67 /2, dose-finding, placebo-controlled, double-blind trial conducted at the University Hospitals of Gen

68 Randomized, double-blind trial conducted in 3 sites in the Pacific Northwes

69 In a randomized, double-blind trial conducted in 399 adults > or = 65 years of a

70 In this double-blind trial conducted on Pemba Island, Tanzania, we rand

71 In this phase 2 randomized, investigator-blinded trial conducted at 2 sexual health clinics, wome

72 ent (ENID) trial was a randomised, partially blinded trial conducted between April 2010 and February

73 Design: A cluster randomized blinded trial conducted between October 2012 and May 201

74 titutes of Health-funded, randomized, single-blinded trial conducted in 12 centers in the United Stat

75 EAN study was a randomized controlled single-blind trial (CPP 2009-A00346-51).

76 As a proof of concept, using a single-blind trial design, we evaluated the progress of 45 pati

77 ME-Meso is a phase II/III randomized, double-blind trial designed to assess efficacy and safety of ni

78 This blinded trial did not show a significant reduction of sy

79 ed in a randomized placebo-controlled double-blind trial (Eastern Cooperative Oncology Group 3999).

80 In a multicenter, double-blind trial, eligible adults with acute pericarditis wer

81 This randomized clinical double-blind trial enrolled participants at 2 clinical sites in

82 Blinded trials enrolled significantly more patients and

83 A randomized, double-blind trial evaluated citalopram at target doses of 10,

84 This randomized, double-blind trial evaluated the efficacy and safety of 16 week

85 tation) was a randomized, controlled, double-blind trial evaluating the effect of etanercept versus p

86 Results from a government-managed blind trial evaluation of the signature library demonstr

87 DESIGN, SETTING, AND PARTICIPANTS: Double-blind trial examining changes in the neural circuits inv

88 In two phase 3, double-blind trials (EXPEDITION 1 and EXPEDITION 2), we randoml

89 was modest (NNT=17), but confirmed in double-blind trials, first- and multi-episode patients, using p

90 The blinded trials found no significant reduction in blood p

91 Few blinded trials have compared conventional therapy consis

92 In a multicenter double-blind trial, hospitalized severely malnourished children

93 We did a parallel-group, randomised, double-blind trial in 11 secondary and two primary care sites i

94 in a placebo-controlled, randomized, double-blind trial in 60 patients with bipolar depression, with

95 We conducted a 26-week, randomized, double-blind trial in adolescent and adult patients (>=12 years

96 In a double-blind trial in Dar es Salaam, Tanzania, we randomly assi

97 oup, multicenter, placebo-controlled, double-blind trial in Japan, 106 ASD individuals (18-48 y.o.) w

98 This study was a randomized, double-blind trial in patients aged >18 years with ABSSSIs.

99 ormed a 15- to 24-month, multicenter, double-blind trial in patients with advanced Parkinson disease

100 This was a 39-center, double-blind trial in patients with definite MS of any course t

101 omized, sham bronchoscopy-controlled, double-blind trial in patients with symptomatic (modified Medic

102 ook a randomised, placebo-controlled, double-blind trial in three South African sites in sexually-act

103 We conducted a randomized, double-blind trial in which adults with acute bacterial skin an

104 ENGAGE AF-TIMI 48 was a randomised, double-blind trial in which patients with atrial fibrillation w

105 We conducted a multicenter, double-blind trial in which patients with type 2 diabetes melli

106 We performed a multicenter, double-blind trial in which patients with type 2 diabetes melli

107 e 2, multicentre, placebo-controlled, double-blind trials in patients with advanced or incurable canc

108 d a pooled analysis of data from four double-blind trials in which 1748 patients were randomly assign

109 nt-level database from 4 prospective, double-blind trials in which 3445 patients were randomized to p

110 stents or bare-metal stents and five double-blind trials in which 3513 patients were randomly assign

111 ecimens obtained during a randomized, double-blinded trial in antiretroviral therapy (ART)-naive HIV-

112 We did this non-blinded trial in two National Health Service (NHS) regio

113 conducted a randomized, open-label, assessor-blinded trial in which patients undergoing primary PCI w

114 f response, the moving away from traditional blinded trials in major depression, and whether preclini

115 This monocentric, placebo-controlled, double-blind trial included 132 patients with grass pollen-indu

116 This randomised double-blind trial included 9270 patients with chronic kidney d

117 In a randomized, multicenter, double-blind trial, inhaled iloprost (5 mug) or placebo was add

118 In a randomized, double-blind trial involving 135 patients with severe eosinophi

119 e Pediatric Heart Network conducted a double-blind trial involving 230 infants with single-ventricle

120 We conducted a 56-week, double-blind trial involving 3731 patients who did not have typ

121 conducted a multicenter, randomized, double-blind trial involving nulliparous women who were at low

122 conducted a multicenter, prospective, double-blind trial involving outpatient adults and children.

123 We performed a randomized, double-blind trial involving patients recruited within 30 days

124 ted a randomized, placebo-controlled, double-blind trial involving patients who had had a mild-to-mod

125 We did a prospective randomised single-blind trial involving patients with large pleural effusi

126 lacebo-controlled, participant- and assessor-blinded trial involving 102 community volunteers with hi

127 Five randomized double-blind trials lasted 12-16 weeks and treated 1,293 patien

128 , placebo-controlled, parallel-group, double-blinded trial (LIPCAL-ALS study) was conducted between F

129 ents exposed to ranolazine during the double-blind trials (n = 972) preceding the ROLE program, annua

130 ST-D) study, a multisite, randomized, single-blind trial of 1,522 Veterans Health Administration pati

131 were initially randomly assigned to a double-blind trial of 12 once-weekly subcutaneous injections of

132 We performed a double-blind trial of 152 adults with gastroparesis at 47 sites

133 We performed a double-blind trial of 190 patients with IBS (according to Rome

134 We performed a double-blind trial of 204 patients (78% Caucasian; 67% female;

135 N, SETTING, AND PATIENTS: Randomized, double-blind trial of 300 women aged 18 to 55 years with acute

136 nducted a single-center, prospective, double-blind trial of 39 patients with mucinous-type pancreatic

137 We performed a single-blind trial of 52 patients with quiescent Crohn's diseas

138 We performed a double-blind trial of 81 patients with active UC randomly assig

139 report the results of a multi-center, double-blind trial of 816 children with acute gastroenteritis w

140 We performed a multicenter, double-blind trial of 99 adults with active EoE randomly assign

141 in a randomized, placebo-controlled, double-blind trial of a nonselective beta-blocker used to preve

142 arge, randomized, placebo-controlled, double-blind trial of a statin with standard-of-care for patien

143 We performed a prospective double-blind trial of adult patients with a recent (<8 weeks) d

144 As part of a randomized, double-blind trial of antifungal prophylaxis in liver transplan

145 A multicenter, randomized, double-blind trial of aspirin (300 mg/day) and folate supplemen

146 sion In this prospective, randomized, double-blind trial of ATLG in unrelated myeloablative HCT, the

147 prospective, multicenter, randomized, double-blind trial of early CCS withdrawal in 386 kidney transp

148 orty-six CAE children in a randomized double-blind trial of ethosuximide, lamotrigine, and valproate

149 In a randomized, placebo-controlled, double-blind trial of exemestane designed to detect a 65% relat

150 nested analysis within a randomized, double-blind trial of ezetimibe/simvastatin versus placebo/simv

151 In a randomized, double-blind trial of healthy volunteers, we found oral Bif195

152 In this multicenter, randomized, double-blind trial of high-dose erythropoietin, we assigned 941

153 year, randomized, placebo-controlled, double-blind trial of intra-articular triamcinolone vs saline f

154 in a randomized, placebo-controlled, double-blind trial of levofloxacin (P = .01).

155 We conducted a randomized, double-blind trial of low-dose methotrexate (at a target dose o

156 ed sunitinib therapy in a randomized, double-blind trial of metastatic castration-resistant prostate

157 nter, randomized, placebo-controlled, double-blind trial of New York Heart Association class II to IV

158 We performed a phase 3, double-blind trial of patients who completed golimumab inductio

159 We then performed a double-blind trial of patients with IBS (mean age, 31 y; range,

160 onducted a single-center, randomized, double-blind trial of perioperative subcutaneous pasireotide in

161 nter, randomized, placebo-controlled, double-blind trial of placebo versus nasal mometasone in adults

162 BIG 1-98 is a randomised, phase 3, double-blind trial of postmenopausal women with hormone recepto

163 na) was an international, randomized, double-blind trial of ranolazine versus placebo in patients wit

164 We conducted a double-blind trial of SER-287 in 58 adults with active mild-to-

165 from an ongoing phase 3, randomised, double-blind trial of TAK-003 in endemic regions of Asia and La

166 se 2, randomized, placebo-controlled, double-blind trial of teplizumab (an Fc receptor-nonbinding ant

167 individually randomized, controlled, double-blind trial of the clinical efficacy of TCV, 28 000 chil

168 performed a multicenter, randomized, double-blind trial of the efficacy and safety of 400, 800, and

169 jects, randomized, placebo-controlled double-blind trial of the nicotinic agonist AZD3480 (also terme

170 We conducted a placebo-controlled, double-blind trial of the prophylactic effect of vitamin A on g

171 nrolled in a prospective, randomized, double-blind trial of traumatic hypovolemic shock, HSD (250 mL)

172 gust 2010, we conducted a randomized, double-blind trial of twice daily 500 mg valacyclovir or placeb

173 cruited for a randomized, controlled, double-blind trial of vitamin D supplementation in pregnancy (4

174 data from two replicate, randomised, double-blind trials of 12 months' duration (Sept 25, 2009 to Oc

175 Results of 2 multicenter, randomized, double-blind trials of 1510 adults with ABSSSI were pooled for

176 nsored randomised placebo-controlled, double-blind trials of 75 mg twice a day oseltamivir in adults.

177 ing the major investment required for double-blind trials of a potential disease-modifying drug in PD

178 id three phase 1, placebo-controlled, double-blind trials of ZPIV with aluminium hydroxide adjuvant.

179 A randomised double-blinded trial of 3 pyrethroid LLIN products (10,571 nets

180 allel, 3-group, placebo-controlled, multiply-blinded trial of 342 adults with mild to moderate asthma

181 pragmatic, multicenter, randomized, observer-blinded trial of 734 high-risk patients aged 50 years or

182 e of this study was to examine outcomes of a blinded trial of initial MTX monotherapy with the option

183 Randomized, blinded trial of intramuscular gene transfer using plasm

184 performed a randomized, placebo-controlled, blinded trial of low-dose (0.5 mg/kg) or high-dose (2 mg

185 After a 1-month blinded trial of patient-assessed twice-per-week tampon

186 overcome the shortcomings of previous double-blinded trials of household water treatment in low-incom

187 Previous blinded trials of household water treatment intervention

188 Meta-analyses of blinded trials of non-drug treatments have not yet prove

189 onducted two prospective, randomized, double-blind trials: one involving children and the other invol

190 In this randomized, double-blind trial, outpatients with schizophrenia (n=55) recei

191 parallel-group design, patient- and observer-blinded trial patients undergoing open elective abdomina

192 In this phase 3, randomised, double-blind trial, patients were enrolled across 141 sites in

193 In this double-blind trial, patients were randomized to receive daily o

194 In a double-blind trial, patients were randomized to tolvaptan 30 mg

195 In this phase 3, double-blind trial, patients were randomly assigned (1:1) to re

196 In this phase 3, double-blind trial, patients were randomly assigned (2:1) to re

197 our-sequence, four-period, crossover, double-blind trial, patients with multiple sclerosis who report

198 In a double-blind trial, patients with peripheral artery disease who

199 se 3, randomized, placebo-controlled, double-blind trials performed from July 15, 2010, to April 16,

200 was conducted for 3 doravirine (DOR) double-blind trials (Phase IIb: P007 [NCT01632345]; Phase III:

201 prospective, multicenter, randomized single-blinded trial (Randomized Trial of IN.PACT Admiral Pacli

202 markers, we conducted a multicenter, double-blind trial, randomizing 278 participants with stage 3b

203 (Dual Antiplatelet Therapy) Study, a double-blind trial, randomly assigned 11 648 patients who had u

204 In a phase 2, open-label, maribavir dose-blinded trial, recipients of hematopoietic-cell or solid

205 In the blind trial set, the panel correctly classified 93.33% A

206 This multicenter, randomized, assessor-blinded trial tested the hypothesis that in elective PCI

207 are no large, prospective, randomized double-blind trials testing the efficacy of IE prophylaxis.) Ho

208 was a randomized, placebo-controlled, double-blind trial that assessed the effects of fludrocortisone

209 IMI 56 was a multicenter, randomized, double-blind trial that enrolled and genotyped 333 patients wit

210 The BIG 1-98 trial is a double-blind trial that randomly assigned 6,193 postmenopausal

211 ial was an international, randomised, double-blind trial that recruited patients with unresectable st

212 This study is the first to demonstrate in a blinded trial that initial MTX monotherapy with the opti

213 r participation, and suggest alternatives to blinded trials that could resolve continued uncertainty

214 y ARIA-GA(2) LEN, to investigate in a double-blind trial the efficacy and safety of AIT in dual-aller

215 In this phase 3 double-blind trial, the authors evaluated the weight profile of

216 of data from randomized, prospective, double-blind trials, the effect of n-3 fatty acids on depressio

217 In blinded trials, the call rate for the eight most common

218 In a blind trial, this sPMCA-based assay specifically amplifi

219 d a phase 1, multicenter, randomized, double-blind trial to assess the safety and immunogenicity of r

220 We undertook a single-blind trial to assess this approach.

221 ted a randomized, placebo-controlled, double-blind trial to assess whether use of the selective COX-2

222 We performed a double-blind trial to compare the efficacy and safety of 2 dosa

223 We did a phase 1 double-blind trial to compare the safety and immunogenicity of

224 ted a randomized, placebo-controlled, double-blind trial to establish the efficacy of atovaquone-prog

225 conducted an exploratory, randomized, single-blind trial to evaluate the efficacy and safety of moxid

226 formed a placebo-controlled, phase 3, double-blind trial to evaluate the efficacy and safety of vedol

227 tin 80 mg vs. 10 mg in a multicenter, double-blind trial to evaluate the impact of atorvastatin on ar

228 We conducted a randomized, double-blind trial to examine the effect of celecoxib on drug-s

229 We performed a multicenter double-blind trial to investigate the efficacy of 3 aspirin reg

230 ting component terms, and we propose further blind trials to test such efforts.

231 We performed a randomized, controlled, blinded trial to determine the maximally tolerated dose

232 may encourage control group participants in blinded trials to cease practicing traditional water tre

233 Randomized, double-blind trial (treatment period, 18 months; median follow-

234 or the 60 training compounds and an unbiased blinded trial using a single hold-out set of 10 addition

235 A randomized, double-blind trial was conducted at ambulatory care centers at

236 TS: A randomized, placebo-controlled, double-blind trial was conducted in 14 gastroenterology practic

237 A randomized, double-blind trial was conducted in 4 countries (Afghanistan, D

238 A parallel randomized single-blind trial was conducted in a primary care outpatient s

239 This randomized, double-blind trial was conducted to determine the optimal dose

240 IIb, multi-institutional, randomized, double-blind trial was to compare the efficacy and safety of GC

241 A randomised, placebo-controlled, double-blind trial was undertaken between October 2014 and July

242 This double-blind trial was undertaken in 255 sites in 30 countries.

243 , sham-controlled, rater-blinded and patient-blinded trial was conducted from 2007-2011.

244 This parallel group, semirandomized double-blinded trial was conducted in a single center in the Un

245 A randomized-order, crossover, double-blinded trial was performed in 14 healthy postmenopausal

246 802, a phase 3 multicenter randomized double-blinded trial, was designed to test whether mycophenolat

247 In this 52-week, randomized, double-blind trial, we assessed efficacy and augmentation in pa

248 In this randomized, double-blind trial, we assessed the efficacy and safety of anti

249 In a randomized, double-blind trial, we assigned 11,506 patients with hypertensi

250 In this randomized, double-blind trial, we assigned 2278 patients with systolic hea

251 In this randomized, double-blind trial, we assigned 3445 patients with symptomatic

252 ternational, multicenter, randomized, double-blind trial, we assigned critically ill adults to receiv

253 In a randomized, controlled, double-blind trial, we assigned patients with chronic coronary

254 In this randomized, double-blind trial, we compared 4 years of therapy with either

255 In this randomized, double-blind trial, we compared apixaban (at a dose of 5 mg twi

256 In this randomised, double-blind trial, we compared degree of pain between standard

257 In a randomized, double-blind trial, we compared hydroxyurea at a fixed dose (ap

258 In this randomized, double-blind trial, we compared parenteral amiodarone, lidocain

259 In a randomized, double-blind trial, we compared tenecteplase plus heparin with

260 In a randomized, double-blind trial, we compared the drug-coated stent with a ve

261 In our prospective randomised double-blind trial, we enrolled adults (>40 years) with karyoty

262 In this multicenter, randomized, double-blind trial, we enrolled participants with definite ALS

263 ternational, multicentre, randomised, double-blind trial, we enrolled patients aged 18-65 years with

264 se 2, placebo-controlled, randomized, double-blind trial, we evaluated a vaccine consisting of recomb

265 In this multicenter, randomized, double-blind trial, we evaluated the efficacy and safety of ora

266 In this double-blind trial, we examined the possibility that rasagiline

267 In a prospective, multicenter, double-blind trial, we randomized 2,466 high bleeding risk pati

268 In a two-site, double-blind trial, we randomized 42 adult patients with stage

269 In a double-blind trial, we randomly assigned (in a 1:1 ratio) adult

270 In a double-blind trial, we randomly assigned 14,264 patients with n

271 In a double-blind trial, we randomly assigned 15,828 patients with s

272 In this double-blind trial, we randomly assigned 2157 patients with acu

273 In this double-blind trial, we randomly assigned 225 men over the age o

274 In this multicenter, double-blind trial, we randomly assigned 3876 patients who had

275 In this double-blind trial, we randomly assigned 5734 patients with CKD

276 In this double-blind trial, we randomly assigned 8442 patients with cla

277 In this double-blind trial, we randomly assigned adults with acute bact

278 In this phase 2b, double-blind trial, we randomly assigned adults with plaque pso

279 In a double-blind trial, we randomly assigned participants with type

280 In this phase 3 randomized, double-blind trial, we randomly assigned patients with hyperpho

281 In this double-blind trial, we randomly assigned patients with intermed

282 In this double-blind trial, we randomly assigned patients with type 2 d

283 In a multicenter, double-blind trial, we randomly assigned patients with type 2 d

284 this multicenter, placebo-controlled, double-blind trial, we randomly assigned women at imminent risk

285 In this phase 3, double-blind trial, we randomly assigned, in a 1:1 ratio, 482 a

286 In this phase 3, randomised, double-blind trial, we recruited eligible patients with histolo

287 nter, placebo-controlled, randomized, double-blind trial, we showed that acquired infections in intub

288 In two double-blind trials, we randomly assigned patients to receive s

289 women participating in a randomized, double-blinded trial, we assessed the effect of periodic presum

290 In this multicenter, randomized, blinded trial, we assigned critically ill adults to rece

291 In this multicenter, parallel-group, blinded trial, we randomly assigned patients with severe

292 The results from 2 parallel-design, double-blind trials were combined.

293 Two phase 3 randomized, double-blind trials were conducted at 154 sites in the United S

294 OCD youth-in a randomized rater-blinded trial-were re-scanned after 12-14 weeks of CBT o

295 In this randomized, double-blind trial, which consisted of a 56-week treatment peri

296 In this phase 3, double-blind trial, which was conducted at 133 centers worldwid

297 med a randomized, placebo-controlled, double-blind trial with 48 obese participants and used function

298 In this eight-center, randomized, double-blind trial with a 2-by-2 factorial design, we compared

299 med a large, multicenter, randomized, double-blind trial with crossover to study the efficacy of GES

300 We conclude that double-blinded trials with consistent application of measuremen